+

WO2008145842A3 - Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique - Google Patents

Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique Download PDF

Info

Publication number
WO2008145842A3
WO2008145842A3 PCT/FR2008/000535 FR2008000535W WO2008145842A3 WO 2008145842 A3 WO2008145842 A3 WO 2008145842A3 FR 2008000535 W FR2008000535 W FR 2008000535W WO 2008145842 A3 WO2008145842 A3 WO 2008145842A3
Authority
WO
WIPO (PCT)
Prior art keywords
preparation
therapeutic use
carboxamide derivatives
triazolopyridine
triazolopyridine carboxamide
Prior art date
Application number
PCT/FR2008/000535
Other languages
English (en)
Other versions
WO2008145842A2 (fr
Inventor
Christian Hoornaert
Original Assignee
Sanofi Aventis
Christian Hoornaert
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE602008001981T priority Critical patent/DE602008001981D1/de
Priority to JP2010503550A priority patent/JP2010524907A/ja
Priority to BRPI0810430-1A2A priority patent/BRPI0810430A2/pt
Priority to AT08787964T priority patent/ATE475661T1/de
Priority to CA002683933A priority patent/CA2683933A1/fr
Priority to AU2008257323A priority patent/AU2008257323A1/en
Priority to MX2009011215A priority patent/MX2009011215A/es
Priority to DK08787964.9T priority patent/DK2146991T3/da
Priority to PL08787964T priority patent/PL2146991T3/pl
Application filed by Sanofi Aventis, Christian Hoornaert filed Critical Sanofi Aventis
Priority to SI200830079T priority patent/SI2146991T1/sl
Priority to EP08787964A priority patent/EP2146991B1/fr
Publication of WO2008145842A2 publication Critical patent/WO2008145842A2/fr
Publication of WO2008145842A3 publication Critical patent/WO2008145842A3/fr
Priority to US12/573,961 priority patent/US7868007B2/en
Priority to IL201416A priority patent/IL201416A0/en
Priority to HR20100573T priority patent/HRP20100573T1/hr
Priority to US12/956,764 priority patent/US20110071161A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Vascular Medicine (AREA)
  • Virology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)

Abstract

L'invention concerne des inhibiteurs de l'enzyme MGL (monoacyl glycerol lipase) de triazolo-pyridine carboxamides, de formule générale (I) Procédé de préparation et application en thérapeutique.
PCT/FR2008/000535 2007-04-18 2008-04-16 Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique WO2008145842A2 (fr)

Priority Applications (15)

Application Number Priority Date Filing Date Title
PL08787964T PL2146991T3 (pl) 2007-04-18 2008-04-16 Pochodne triazolopirydyno-karboksamidów, ich wytwarzanie i zastosowanie terapeutyczne
BRPI0810430-1A2A BRPI0810430A2 (pt) 2007-04-18 2008-04-16 Derivados de triazolo piridina - carboxamidas, o respectivo preparo e a respectiva aplicação em terapêutica
AT08787964T ATE475661T1 (de) 2007-04-18 2008-04-16 Triazolopyridin-carboxamid-derivate sowie ihre herstellung und therapeutische verwendung
CA002683933A CA2683933A1 (fr) 2007-04-18 2008-04-16 Derives de triazolopyridine-carboxamides, leur preparation et leur application en therapeutique
AU2008257323A AU2008257323A1 (en) 2007-04-18 2008-04-16 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
MX2009011215A MX2009011215A (es) 2007-04-18 2008-04-16 Derivados de triazolopiridina carboxamida, su preparacion y su aplicacion terapeutica.
DK08787964.9T DK2146991T3 (da) 2007-04-18 2008-04-16 Triazolopyridin-carboxamid-derivater, fremstilling af samme samt terapeutisk anvendelse deraf
DE602008001981T DE602008001981D1 (de) 2007-04-18 2008-04-16 Stellung und therapeutische verwendung
SI200830079T SI2146991T1 (sl) 2007-04-18 2008-04-16 Derivati triazolopiridin karboksamidov njihova priprava in njihova terapevtska uporaba
JP2010503550A JP2010524907A (ja) 2007-04-18 2008-04-16 トリアゾロピリジンカルボキサミド誘導体、その調製およびその治療的使用
EP08787964A EP2146991B1 (fr) 2007-04-18 2008-04-16 Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
US12/573,961 US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof
IL201416A IL201416A0 (en) 2007-04-18 2009-10-11 Triazolopyridine carboxamide derivatives, preparation thereof and theraputic use thereof
HR20100573T HRP20100573T1 (hr) 2007-04-18 2010-10-19 Triazolopiridinkarboksamidni derivati, njihovo dobivanje i njihova upotreba u terapiji
US12/956,764 US20110071161A1 (en) 2007-04-18 2010-11-30 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0702807 2007-04-18
FR0702807A FR2915197B1 (fr) 2007-04-18 2007-04-18 Derives de triazolopyridine-carboxamides, leur preparation et leur application therapeutique.

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/573,961 Continuation US7868007B2 (en) 2007-04-18 2009-10-06 Triazolopyridine carboxamide derivatives, preparation thereof and therapeutic use thereof

Publications (2)

Publication Number Publication Date
WO2008145842A2 WO2008145842A2 (fr) 2008-12-04
WO2008145842A3 true WO2008145842A3 (fr) 2009-01-22

Family

ID=38739381

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2008/000535 WO2008145842A2 (fr) 2007-04-18 2008-04-16 Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique

Country Status (26)

Country Link
US (2) US7868007B2 (fr)
EP (1) EP2146991B1 (fr)
JP (1) JP2010524907A (fr)
KR (1) KR20090130060A (fr)
CN (1) CN101657451A (fr)
AR (1) AR066103A1 (fr)
AT (1) ATE475661T1 (fr)
AU (1) AU2008257323A1 (fr)
BR (1) BRPI0810430A2 (fr)
CA (1) CA2683933A1 (fr)
CY (1) CY1111601T1 (fr)
DE (1) DE602008001981D1 (fr)
DK (1) DK2146991T3 (fr)
ES (1) ES2348969T3 (fr)
FR (1) FR2915197B1 (fr)
HR (1) HRP20100573T1 (fr)
IL (1) IL201416A0 (fr)
MX (1) MX2009011215A (fr)
PL (1) PL2146991T3 (fr)
PT (1) PT2146991E (fr)
RS (1) RS51462B (fr)
RU (1) RU2009142430A (fr)
SI (1) SI2146991T1 (fr)
TW (1) TW200906401A (fr)
UY (1) UY31036A1 (fr)
WO (1) WO2008145842A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8772318B2 (en) * 2008-11-14 2014-07-08 The Scripps Research Institute Methods and compositions related to targeting monoacylglycerol lipase
JP5657566B2 (ja) * 2008-12-24 2015-01-21 バイアル ポルテラ アンド シーエイ エス エイＢＩＡＬ−Ｐｏｒｔｅｌａ ＆ Ｃａ， Ｓ．Ａ． 医薬品
US8445477B2 (en) 2009-04-22 2013-05-21 Janssen Pharmaceutica, Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
WO2011140296A1 (fr) * 2010-05-05 2011-11-10 Infinity Pharmaceuticals Triazoles utilisés comme inhibiteurs d'acides gras synthase (fasn)
CA2809991A1 (fr) * 2010-09-03 2012-03-08 Janssen Pharmaceutica Nv Di-azetidinyl diamide en tant qu'inhibiteurs de monoacylglycerol lipase
CN103080103A (zh) 2010-09-27 2013-05-01 詹森药业有限公司 作为单酰甘油脂肪酶抑制剂的氧代哌嗪-氮杂环丁烷酰胺和氧代二氮杂*-氮杂环丁烷酰胺
KR20130140020A (ko) 2010-10-22 2013-12-23 얀센 파마슈티카 엔.브이. 모노아실글리세롤 리파아제 억제제로서의 아미노-피롤리딘-아제티딘 다이아미드
US8513423B2 (en) 2010-10-22 2013-08-20 Janssen Pharmaceutica, Nv Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors
EP2567959B1 (fr) 2011-09-12 2014-04-16 Sanofi Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
HUE067912T2 (hu) 2018-08-13 2024-11-28 Hoffmann La Roche Új heterociklusos vegyületek, mint monoacil-glicerin-lipáz inhibitorok
PE20211380A1 (es) * 2018-08-13 2021-07-27 Hoffmann La Roche Nuevos compuestos heterociclicos como inhibidores de monoacilglicerol lipasa
TW202035409A (zh) 2018-09-28 2020-10-01 比利時商健生藥品公司 單醯基甘油脂肪酶調節劑
CA3242372A1 (fr) 2021-12-29 2023-07-06 Psy Therapeutics, Inc. Inhibition de la monoacylglycerol lipase (magl)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138657A1 (fr) * 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Heterocycles bicycliques en tant que modulateurs de recepteur de cannabinoide 1

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0100624D0 (en) * 2001-01-10 2001-02-21 Vernalis Res Ltd Chemical compounds VII
DE10247680B4 (de) * 2002-10-12 2005-09-01 Aventis Pharma Deutschland Gmbh Neue bicyclische Inhibitoren der Hormon Sensitiven Lipase
DE102004005172A1 (de) * 2004-02-02 2005-08-18 Aventis Pharma Deutschland Gmbh Indazolderivate als Inhibitoren der Hormon Sensitiven Lipase
DE102005049954A1 (de) * 2005-10-19 2007-05-31 Sanofi-Aventis Deutschland Gmbh Triazolopyridin-derivate als Inhibitoren von Lipasen und Phospholipasen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006138657A1 (fr) * 2005-06-17 2006-12-28 Bristol-Myers Squibb Company Heterocycles bicycliques en tant que modulateurs de recepteur de cannabinoide 1

Also Published As

Publication number Publication date
AU2008257323A1 (en) 2008-12-04
PT2146991E (pt) 2010-10-04
SI2146991T1 (sl) 2010-11-30
TW200906401A (en) 2009-02-16
RS51462B (en) 2011-04-30
RU2009142430A (ru) 2011-05-27
PL2146991T3 (pl) 2011-01-31
ATE475661T1 (de) 2010-08-15
HRP20100573T1 (hr) 2010-11-30
EP2146991B1 (fr) 2010-07-28
CN101657451A (zh) 2010-02-24
BRPI0810430A2 (pt) 2014-10-14
IL201416A0 (en) 2010-05-31
ES2348969T3 (es) 2010-12-17
UY31036A1 (es) 2008-11-28
WO2008145842A2 (fr) 2008-12-04
US20100035893A1 (en) 2010-02-11
AR066103A1 (es) 2009-07-22
FR2915197A1 (fr) 2008-10-24
MX2009011215A (es) 2009-11-02
FR2915197B1 (fr) 2009-06-12
CY1111601T1 (el) 2015-10-07
DE602008001981D1 (de) 2010-09-09
DK2146991T3 (da) 2010-11-22
CA2683933A1 (fr) 2008-12-04
KR20090130060A (ko) 2009-12-17
US20110071161A1 (en) 2011-03-24
JP2010524907A (ja) 2010-07-22
US7868007B2 (en) 2011-01-11
EP2146991A2 (fr) 2010-01-27

Similar Documents

Publication Publication Date Title
WO2008145842A3 (fr) Dérivés de triazolopyridine-carboxamides, leur préparation et leur application en thérapeutique
HK1101284A1 (en) Derivatives of alkylpiperazine-and alkylhomopiperazine-carboxylates, preparation method thereof and use of same as faah enzyme inhibitors
WO2007106236A3 (fr) Modulateurs de kinase a base de pyrrolo-pyridine
WO2008025857A3 (fr) Nouveau procédé de traitement de maladies inflammatoires
WO2007149907A3 (fr) Puissants inhibiteurs de parp
IL177534A0 (en) Derivatives of piperidinylalkylcarbamates, preparation method thereof and use of same as faah enzyme inhibitors
EP1898903B8 (fr) Inhibiteurs de l'activite akt
TN2010000203A1 (en) Beta-lactamase inhibitors
WO2010003313A8 (fr) Chlorhydrate d’icotinib, synthèse, forme cristallographique, combinaison médicale et utilisations
WO2007084557A3 (fr) Azaindoles utiles comme inhibiteurs de janus kinases
WO2010127099A3 (fr) Compositions pharmaceutiques comprenant de l'epa et un agent cardiovasculaire et leurs procédés d'utilisation
WO2010074588A3 (fr) Composés pharmaceutiques
TW200745047A (en) Heterocyclic compounds
ME02268B (fr) Processus de préparation d'électrodes modifiées, électrodes préparées avec ce processus, et biocapteurs enzymatiques comportant ces électrodes
WO2009085270A3 (fr) Traitement d'états fibreux
WO2009089263A3 (fr) Nouvelles compositions et procédés d'utilisation
WO2007125105A3 (fr) Activateurs de la glucokinase benzamidique
WO2010030983A3 (fr) Inhibiteurs pyrazole carboxamide du facteur xa
WO2010048358A3 (fr) Inhibiteurs à base d'éthoxyphénylméthyle de sglt2
MX2009010485A (es) Derivados de imidazolidinacarboxamida como inhibidores de lipasas y fosfolipasas.
AU2007243282A8 (en) Compositions and methods for the treatment of cardiovascular disease
WO2010062506A3 (fr) Inhibiteurs de cyp17 décahydro-1h-indénoquinolinone et décahydro-3h-cyclopentaphénanthridinone
WO2007081808A3 (fr) Composes et derives pour le traitement d’etats medicaux par modulation de l’activite de la lipase hormono-sensible
IL198286A (en) Use of alkaneuite indazole acid for the preparation of medical preparations to lower triglyceride, cholesterol and sugar levels
TNSN08531A1 (en) Phenylacetic acid derivatives as cox - 2 inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200880012319.9

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08787964

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2008787964

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 201416

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3545/KOLNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2683933

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2010503550

Country of ref document: JP

Kind code of ref document: A

Ref document number: 20097021600

Country of ref document: KR

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/A/2009/011215

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 2008257323

Country of ref document: AU

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2009142430

Country of ref document: RU

WWE Wipo information: entry into national phase

Ref document number: P-2010/0434

Country of ref document: RS

ENP Entry into the national phase

Ref document number: PI0810430

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20091019

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载